Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
Nadda underlined that India’s policy framework is aligned with this transformation
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
Subscribe To Our Newsletter & Stay Updated
